Purpose: It is well known that cancers exploit immune checkpoints (programmed death 1 receptor (PD-1) and its ligand (PD-L1)) to evade anti-tumor immune responses. Although immune checkpoint (IC) blockade is a promising approach, not all patients respond. Hence, imaging of tumor-infiltrating lymphocytes (TILs) is of high specific interest, as they are known to express PD-1 during activation and subsequent exhaustion in the tumor microenvironment and are thought to be potentially predictive of therapeutic responses to IC blockade. Correspondence to: Sanjiv Gambhir; e-mail: sgambhir@stanford.edu Conclusions: Our immunoPET study clearly demonstrates specific imaging of human PD-1-expressing TILs within the tumor and lymphoid tissues. This suggests these anti-human-PD-1 tracers could be clinically translatable to monitor cancer treatment response to IC blockade therapy.
Introduction
There is an urgent need to develop diagnostic tools for improved clinical management of cancer patients. To select cancer treatments, and to evaluate their efficacy, current practice utilizes sampling of peripheral blood to analyze circulating tumor cells or other biomarkers in the blood, or invasive techniques such as biopsies to grade a tumor by histology. Although positron emission tomography (PET) with 2-deoxy-2-[ Recently, immune checkpoint blockade of cytotoxic lymphocyte antigen-4 (CTLA-4), programmed death-1 receptor (PD-1), and/or programmed death-1 ligands (PD-L1/ L2) has emerged as a powerful strategy for cancer therapy [1] [2] [3] . This has been well validated in human patients using anti-CTLA-4 (ipilimumab, tremelimumab), anti-PD-1 (nivolumab, pembrolizumab), and anti-PDL-1 (MED14736) antibodies for metastatic melanoma and lung cancer [4] [5] [6] . Specifically, blockade of the PD-1 signaling axis using anti-PD-1 monoclonal antibodies (mAb) has shown encouraging results in restoring suppressed anti-tumor immunity [7] [8] [9] [10] [11] [12] . These include nivolumab (Bristol-Myers Squibb, PD-1), pembrolizumab (Merck, PD-1), and MSB0010718C (Merck, PD-L1). Thus, it is becoming clear that signaling through the PD-1 axis significantly dampens anti-tumor immune responses [13] [14] [15] [16] [17] .
PD-1 is part of the immunoglobulin (Ig) B7 receptor family; a transmembrane protein with three protein domains containing 288 amino acids [16, 18] . Its activity and expression are enhanced by IFN-γ, TNF-α cytokine secretion, and PD-L1. PD-1 is expressed on many cell types such as CD4+, CD8+ effector T cells, natural killer (NK) T cells, B cells, and some dendritic cells [15, 16] . Expression of this protein on CD8+ T cells diminishes the effector function of the CD8+ T cells [19, 20] . PD-1 is also expressed on CD4 + Foxp3+ regulatory T cells (Tregs), which are known to generate immunosuppression in the tumor microenvironment [19, 20] . Consequently, PD-1 pathway stimulation affects T cell immunoreactivity in the tumor microenvironment.
Clinical blockade of immune checkpoints has resulted in an increased prevalence of late-stage patients with progression free survival beyond the 2-year mark, suggesting the benefit of immune checkpoint inhibitors over conventional regimens [6, 15] . Recent randomized clinical trials indicate that anti-PD-1 therapy (nivolumab and pembrolizumab) has demonstrated a survival advantage, including patients who progressed after treatment with ipilimumab [21, 22] . However, despite encouraging clinical results, many cancer patients do not respond to clinical checkpoint blockade. Thus, patients treated with immunotherapies commonly appear with tumor growth or incomplete remission prior to relapse [23] . Though anatomic imaging has been regularly performed [24, 25] to measure tumor size and to monitor therapy, a compelling need exists for molecular imaging to accurately predict which patients are most likely to benefit from anti-PD-1/PD-L1 treatment and to establish assessment criteria.
Due to tumor heterogeneity, some tumors are able to evade immune-mediated therapy, hence relevant biomarkers are necessary to guide and monitor therapy. PD-1 expression on tumor-infiltrating lymphocytes may serve as a good biomarker to predict responders to checkpoint blockade [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . It has been difficult to determine the true prognostic value of PD-1 using biopsies in conjunction with immunohistochemistry (IHC) methods, as the expression is highly heterogeneous within both the primary tumor and metastases.
Hence, there is a convincing need to detect and quantify the PD-1 expression levels in patients, by a non-invasive method, such as PET imaging. This will provide more accurate information to select eligible candidates for PD-1 immunotherapies. In this report, we present a novel anti-human PD-1 immunoPET tracer that is capable of specifically imaging PD-1 expression on human tumor-infiltrating lymphocytes (TILs). Until now, there has been no clinically approved PET tracer available for imaging global PD-1 expression to monitor therapy. In this context, our new tracer would be readily translatable to human patients, and would fill this need once FDA approved.
Cell Lines and Instruments
The 293T and A-375 cell lines used in this study were obtained from American Type Culture Collection (www.atcc.com, ATCC® number CRL-3216 and CRL-1619, respectively). These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (4.5 g/l glucose). Media was supplemented with 10 % fetal calf serum (FCS), 2 mmol/L glutamine, 100 units/ml penicillin, 100 μg streptomycin, and 0.25 μg/ml fungizone. All media and additives were obtained from Invitrogen Corporation (Carlsbad, CA, USA). The human PD-1 expressing 293T cell line was developed in-house using 293T transfected with pC Puro Ubx hPD1-IRES-eGFP cDNA and Lipofectamine 3000. The transfected cells were incubated with 3 ng/ml of puromycin in DMEM media for several days for luciferase positive cell selection. FACS was performed with anti-human PD-1 antibody to enrich hPD1-positive cells.
High-performance liquid chromatography (HPLC) was performed on an HPLC-Ultimate 3000 (Thermo Scientific, Waltham, MA, USA) with a SEC 2000 LC column (300 × 7.8 mm) with 5 μm, hydrophilic-bonded silica support of 400-Å pore size (Phenomenex, Torrance, CA, USA) with an ultraviolet detector and an online radioactivity detector. An instant thin-layer chromatography strip (Biodex Medical Systems, Shirley, NY) with saline as mobile phase was employed as an additional quality test for purity of the tracer.
Preparation of Immunoconjugate and ImmunoPET Tracer
The anti-hPD-1 Keytruda antibody was purified by Phenomenex size-exclusion chromatography (SEC) 2000 (Torrance, CA, USA) HPLC with phosphate buffer solution (pH 8.0) and buffer exchanged with 1 M HEPES/0.1 M Na2CO3 (pH 8.5 ± 0.5) and concentrated to ∼5 mg/ml using a Vivaspin 30-kDa centrifugal filter (Thermo Fisher Scientific, Waltham, MA, USA; catalog no. VS2021). Df-Keytruda was prepared according to published procedure by conjugating Df-NCS to Keytruda in a microfuge tube to generate Df-Keytruda to chelate Zr-89 [39] . Coupling conditions and detailed experimental procedures of Df-or DOTA-Keytruda are provided in the supplemental section. The number of chelators (c) coupled per antibody (a) i.e., c/a was estimated with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) by comparison of unmodified Keytruda, Df-Keytruda, and DOTA-Keytruda [31] .
In Vitro Live Cell-Binding Assay of the Immunoconjugate Binding affinities of Df-Keytruda and DOTA-Keytruda were compared with unmodified Keytruda, tested on transiently transfected hPD-1 expressing 293T cells and analyzed by flow cytometry. Briefly, Keytruda, Df-Keytruda, and DOTA-Keytruda were diluted to 1 nM solution in FACS buffer Dulbecco's PBS. Staining was performed in 96-well microtiter plates (V-bottom). The experimental procedure is described in detail in the supplemental section. Data was analyzed by FlowJo FACS analysis software version 10.1 (Tree Star, Ashland, OR, USA).
Synthesis of [ 89

Zr] Keytruda
The reaction vial was prepared with the following reactants: while gently shaking, 100-200 μl of 0.1 M oxalic acid, 89 Zr isotope (220-230 MBq; 500 μl), and 1M Na 2 CO 3 (80 ± 20 μl) were added into the reaction vial and incubated for 3 min at room temperature. After 3 min, 200 ± 50 μl of 0.5 M HEPES (pH 7 ± 0.5) was added, and finally, DfKeytruda1 0.5 -0.75 mg (100 -150 μl) was added and the pH readjusted to 8 ± 0.5 using 0.5 M HEPES and incubated at 37°for 60 min. 
Purity, Immunoreactivity, and Stability of the Two Tracers
The purity of the radiotracers was tested by TLC as well as SEC-2000 radio-HPLC. To measure the immunoreactivity of the tracer, a live cell-binding assay was performed as described previously [40, 41] . Immunoreactivity assay conditions are explained in the supplemental section. Immunoreactivity was computed by linear regression analysis by plotting of (Y axis: total/bound) activity versus (X axis: 1/[normalized cell concentration]), and calculated as 1/y-intercept × 100 [39, 40] .
The serum stability of the [
89
Zr] Keytruda tracer was tested with normal human serum (Sigma Aldrich, St Louis, MO) and incubated at 37°C. Serum with tracer mixture (100 μL) was aliquoted and analyzed by radio-HPLC at two different time points (4 and 48 h), and radio-HPLC elution was collected as 1-ml fractions and counted in a gamma counter. Percent activity of each fraction was computed to measure tracer stability in serum.
Animal Studies
Animal studies were approved by the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University. NSG (NOD.Cg-Prkdc scid Il2rg tm1wjl /SzJ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in-house in an AAALAC-accredited facility. The average weight of the NSG mice was 22.0 ± 3.0 g. Humanized NSG mice (hNSG) were developed as per the methods published elsewhere [42] and utilized for the immunoPET imaging study. NSG-ctl mice did not receive hPBMC. The hPBMCs were isolated from normal human blood and tested by FACS for the expression of huCD45 and hPD-1+ lymphocytes. Positively tested hPBMCs (5 × 10 6 cells) were injected via tail-vein in each of the NSG mice. Three days after implantation, hNSG mice were screened by FACS analysis for in vivo hPBMC engraftment. hNSG mouse blood was collected and stained for anti-human CD45 for the confirmation of hPBMC engraftment. Two groups of NSG mice (hNSG-nblk and NSG-ctl), (n = 4) were imaged at 1, 4, 18, 24, 48, 72, 96, 120, and 144 h using small animal PET/CT at the Stanford small animal imaging center. 
Small Animal ImmunoPET-CT Imaging
To acquire the PET-CT images, the immunoPET tracers were administered to a lightly restrained mouse via a lateral tail vein injection. PET-CT imaging was performed on a Siemens Inveon small-animal multimodality PET/CT system (Preclinical Solutions; Siemens Healthcare Molecular Imaging, Knoxville, TN). The PET-CT images acquired were reconstructed with the two-dimensional ordered-subset expectation maximization (OSEM 2D) algorithm [41] . The microPET scanning (default settings with energy window of 350 to 650 keV) was performed at the following time points after the tracer injection: 1 and 4 h, for 3 min; 18 and 24 h, for 5 min; 24, 48, and 72 h, for 10 min; 96-144 h for 15 min scans. Regions of interest (ROIs) of organs of interest were computed using Inveon Research Workplace software (Preclinical Solutions; Siemens Healthcare Molecular Imaging, Knoxville, TN). ROI volume was converted to radioactivity concentration in counts per minute (cpm) by using a predetermined conversion factor. The %ID/g tissue was estimated by dividing each tissue's cpm obtained from the region of interest by the injected dose. Zr] Keytruda (200 μl, corresponding to 3.7 ± 0.4 MBq, 15-16 μg) was administered to two groups of mice (n = 4, per group), NSG-ctl (non-PBMC) and NSG-nblk (with human PBMC), which were sacrificed after 144 h post scanning. The [
64 Cu] Keytruda tracer (200 μl, corresponding to 7.4 ± 0.4 MBq, 20-25 μg) was administered in three groups of mice (NSG-ctl, NSG-blk, and NSG-nblk) that were sacrificed after 48 h PET-CT scan. Animals were euthanized by CO 2 gas asphyxiation for biodistribution studies. Organs were removed, rinsed in PBS, dried in air for 5 min, and weighed and counted in a gamma-counter to determine corresponding radioactivity associated with each of the tissues. The immunoPET tracer dose uptake by each organ was determined by measuring the total number of cpm. Count data were background subtracted and decay corrected to the time of injection, and the percent-injected dose per gram (%ID/g) for each tissue sample was calculated by normalization to the total activity injected.
Statistical analysis: unpaired student's t test was used for data comparisons. P values less than 0.05 were considered statistically significant.
Results
We have prepared two immunoPET tracers ( 
Synthesis of the immunoPET Pre-Cursor (Df/ DOTA-Keytruda)
Keytruda is a fully humanized IgG4 antibody against human PD-1 receptor protein approved by the FDA (September, 2014) for the treatment of unresectable or metastatic melanoma [22, 43] . The immunoPET pre-cursor (DfKeytruda) was prepared by covalently coupling Df-Bz-NCS (Df) to the lysine groups of Keytruda at pH 8.0. Precursor synthesis was performed in three different conditions (in duplicate) by addition of 2.5, 5, and 7.5 M excess of Df to Keytruda, incubated at 37°C for 60 min, at pH 8.0. The reaction products were purified by SEC-2000 HPLC and tested for chelate per antibody (c/a) by mass spectrometry. The best immunoconjugation was achieved at 7.5 M excess of Df to Keytruda, resulting in a reproducible Df/ Keytruda ratio of 1.1 ± 0.2, (mean ± SD, n = 3) Df per antibody, confirmed by the MALDI-TOF (Fig. 1a , and Suppl. Fig. S1 MALDI spectrum). The Df-Keytruda (filled bar) was tested for its binding ability using hPD-1 expressing 293-T cells, which exhibit specific binding toward the hPD-1 protein, when compared to the naive 293T cells (open bar) (Suppl. Fig. S2, FACS 89 Zr] in 0.5 M HEPES (pH 7.0-7.5) buffer yielded 960 % after purification. In Fig. 1a , the radio-HPLC analysis confirmed that the immunoPET tracer purity is 998 % (mean ± SD 98.0 ± 1.8 %) monomeric antibody with specific activity of 0.21 ± 0.07 MBq/μg. Figure 1b shows that the binding fraction of the [
89 Zr] Keytruda tracer tested on human PD-1-expressing 293T cells was 74 %. The radiochemical stability in normal human serum was 985 % tested for up to 48 h (Fig. 1c) . Overall, these assays confirmed that the immunoPET tracer was of high quality and good enough to target specifically to human PD-1 receptor. Similarly, [ 64 Cu] Keytruda showed 995 % purity and 72 ± 1.4 % (mean ± SD) immunoreactivity (Suppl. Table 1 ).
Humanized NSG Mouse Model
NSG mice are well known for the engraftment of human hematopoietic stem cells (HSC) or human PBMC (hPBMC) to create humanized mouse models to test drugs [44] [45] [46] [47] [48] [49] . We carefully chose this animal model (NSG mice), to avoid cross-reactivity of murine PD-1, which does not express T cells and lack an immune system. Figure 2a shows the quality control of the hPBMC used to create hNSG mice. The assay was performed for the measurement of the human CD45+ cells in hPBMC, and the results indicated 995 % of the cells were human CD45+. Figure 2b demonstrates the percent of human PD-1+ cells in hPBMC stained by Keytruda, biotin-anti-human Fc secondary antibody, followed by streptavidin-APC. The left panel is unstained hPBMC (control), and the right panel is stained for antihuman PD-1, which shows that 17 % of cells were human PD-1+. This assay illustrated the binding ability of Keytruda against human PD-1 in hPBMC, which is used for the engraftment of NSG mice. After hPBMC engraftment, mice were further tested for the presence of hPBMC by analyzing the presence of human CD45+ cells in the hNSG mouse blood pool. FACS data clearly indicated the successful engraftment of hPBMC in all hNSG mice, whereas the control NSG mouse group showed no human CD45+ cells in the blood (Fig. 2c) . In addition, in vitro binding analysis was performed to determine Keytruda cross reactivity using human PBMCs and rat PBMCs by FACS (Suppl. Fig S3) . This test clearly indicated no noticeable binding with rat PBMCs.
Small Animal PET and CT Imaging Figure 3 represents PET-CT images (scanned at 24, 72, and 144 h) which indicate that immunoPET tracer binds to human TILs that are homing into the tumor and spleen, compared with the control NSG mice. PET signal appearing at the mouse organs is associated with tracer that specifically binds to human-PD-1 protein expressed on human lymphocytes. However, the PET signal arising from the liver could be non-specific due to slow clearance of the immunoPET tracer. To obtain immunoPET tracer clearance over this period of time, PET scans were performed at various time points for up to 144 h after tracer injection. Figure 3b shows that the spleen uptake (ROI mean %ID/g ± SD) by NSG-ctl and hNSG-nblk mice are 11.86 ± 1.27 and 13.16 ± 0.7 for 4 h and 12.94 ± 2.13 and 16.43 ± 1.42 for 24 h, respectively (P = 0.01 and 0.01 for 4 and 24 h, respectively). Figure 3c indicates that the tumor to muscle ratio of [ 89 Zr] Keytruda uptake by NSG-ctl and hNSG-nblk mice are 18.9 ± 3.8 and 34.8 ± 2.9 for 4 h (P = 0.0004), and at 24 h, the uptake ratio increased to 20.3 ± 4.6 and 35.0 ± 2.5 (P = 0.002). Figure 4 shows the ROI quantification (mean ± SD) ( Fig. 4a : heart and liver) (Fig. 4b : spleen and tumor) results performed on organs of interest of PET-CT images (Fig. 3a) at various points. At 24 h, the tracer uptake by non-specific organs such as heart and liver of hNSG mice were 0.86 ± 0.15 and 2.5 ± 0.28, respectively, and dropped to 0.37 ± 0.08 and 1.84 ± 0.27, respectively, at 144 h (Fig. 4a) . In Fig. 4b , ROI of immunoPET shows that the PET signal obtained from the spleen and tumor was due to humanPD-1 that binds to lymphocytes homing into the organs. The maximum uptake observed was at 24 h by the spleen of hNSG (16.4 ± 1.4 %) and control NSG (12.9 ± 2.1 %). However, the tumor uptake by hNSG (3.8 ± 0.4 %) was high compared to the control NSG (2.9 ± 0.9 %). As was expected, the human PD-1 tracer homed well into the tumor and spleen of melanoma xenografts. 
7-8 MBq of [
64 Cu] Keytruda (20-22 μg of DOTAkeytruda). In Fig. 5a , representative PET-CT images (scanned at 4 and 24 h) indicate that immunoPET tracer homing into the tumor of hNSG-nblk mice increased compared with the NSG-ctl and hNSG-blk mice. In Fig. 5b , the clearance profile of the tracer from heart and liver, the tracer presence was reduced as early as at 24 h. At this time point, the ROI mean %ID/g ± SD by NSG-ctl, hNSG-blk, and hNSG-nblk mice was 2.8 ± 0.7, 3.1 ± 0.5, and 3.6 ± 0.5, respectively for heart; 3.4 ± 0.6, 4.6 ± 0.6, and 5.6 ± 0.8, respectively for liver; and the tumor uptake was 2.5 ± 1.1, 4.4 ± 1.3, and 6.4 ± 0.7, respectively.
In Fig. S4a , ROI of [
64 Cu] Keytruda immunoPET shows the PET signal obtained from the spleen. The tracer uptake by NSG-ctl and hNSG-blk and hNSG-nblk mice was 9.4 ± 2.6, 11.8 ± 2.1, and 13.7 ± 2.1 for 4 h and 9.7 ± 1.9, 11.1 ± 1.5, and 17.5 ± 2.1 for 24 h, respectively. The maximum uptake observed was at 24 h by the spleen of hNSG-nblk (17.5 ± 2.1 %). Figure S4b indicates that the tumor to muscle ratio of tracer uptakes by NSG-ctl, hNSGblk, and hNSG-nblk mice was 5.7 ± 1.4, 19.9 ± 4.5, and 28.5 ± 6.6 for 4 h (ctl verses nblk P = 0.002), and at 24 h, the uptake ratio increased to 7.5 ± 3.7 and 29.9 ± 1.7, 48 ± 8.7 (ctl verses nblk P = 0.002). 89 Zr] Keytruda (3.2 MBq/16 μg/200 μl) in NSG (control) and hNSG mice bearing A375 melanoma. L liver, H heart, T tumor, S spleen. b ROI quantification of immunoPET tracer homing (mean %ID/g ± SD) into spleen of control NSG (NSG-ctl) (n = 4) and hNSG-nblk (non-blocking) (n = 4), after 4 and 24 h postinjection. *P G 0.05; **P G 0.01. c Tumor to muscle background ratios were computed from ROI at 4 and 24 h. NSG and hNSG mice were also compared. The tumor-to-muscle ratio (TMR) of hNSG was significantly higher than NSG control mice (p = 0.001).
This was further confirmed by scanning the ex vivo organs by PET-CT (Fig. S5) . Figure S5 illustrates the PET-CT coronal image of a humanized NSG mouse ( uptake; specifically the blood, heart, lungs, liver, spleen, kidney, muscle, bone, and tumor on CT and PET-CT, respectively. From these images, it is evident that [
89 Zr] Keytruda tracer specifically targeted the human PD-1 that is associated with lymphoid organs. Suppl. Fig. S5 clearly shows that the tracer uptake by spleen and tumor are due to human TILs homing into these organs. Fig. 6a ) by tumor in NSG-ctl and hNSG-nblk mice was (mean % ID/g ± SD) 1.8 ± 0.4 and 3.2 ± 0.7 (P = 0.02), respectively. After 144 h BioD, tumor to muscle ratio of the tracer was shown as ∼15 and 45 for hNSG-ctl and NSG-nblk, respectively. The tracer uptakes (mean %ID/g ± SD) of hNSGnblk in clearance organs such as liver and kidney are 4.6 ± 2.1 and 1.6 ± 0.2 at 144 h. The [ 64 Cu] Keytruda tracer uptakes by tumor in hNSG-nblk, hNSG-blk, and NSG-ctl mice were (mean % ID/g ± SD) 9.4 ± 2.5, 5.9 ± 2.1 (hNSG-nblk vs hNSGblk: P = 0.05), and 5.7 ± 0.6 (NSG-ctl vs hNSG-blk; P = 0.002), respectively. The spleen uptake (mean %ID/ g ± SD) of hNSG-nblk, hNSG-blk, and NSG-ctl mice was (mean % ID/g ± SD) 6.3 ± 1.0, 10.5 ± 2.0 (hNSG-nblk vs hNSG-blk; P = 0.005), and 6.7 ± 2.2 (hNSG-nblk vs hNSG-ctl; P = 0.03), respectively. The uptake (mean %ID/g ± SD) of hNSG-nblk in clearance organs such as liver and kidney are 7.9 ± 1.6 and 4.9 ± 0.9 at 48 h. After 48 h, BioD (Fig. 6b) the tumor-to-muscle ratio of hNSG-nblk was 12.3 and the NSG-ctl was 5.4.
Biodistribution Studies of
Discussion
Targeting immune checkpoints for cancer therapy is showing clinical success with durable responses and long-term survival in some patients for greater than 10 years [2, 50] . The FDA has already approved several immune checkpoint blockade therapeutics including pembrolizumab (anti-PD-1 IgG4 by Merck), nivolumab (anti-PD-1 human IgG4 mAb by Bristol-Myers Squibb), and atezolizumab (anti-PD-L1 human IgG mAb, MPDL3280A, by Roche) [11] . Other immune checkpoint-associated pathways are also under current investigation (e.g., TIM-3, BTLA, and VISTA). Taken together, all of these studies show that blocking immune checkpoint receptors or ligand pathways enhances effector T cell function in the tumor microenvironment [8, 30] . That said, it is still unclear whether the blockade of a single immune checkpoint is sufficient to drive anti-tumor immunity or if combinatorial strategies will have to be employed in most cases. While the complex mechanisms governing anti-tumor immunity are still not largely understood, homing of cytotoxic TILs into the tumor interstitium is very much needed for patients to respond to immune checkpoint blockade therapy, and thus, these TILs could potentially serve as a predictive biomarker.
The ability to measure activated tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment could provide valuable information for selecting which patients would respond to immune checkpoint blockade therapy. It is possible to measure activated TILs directly by cell surface protein markers such as the PD-1 receptor. Presently, PD-1 is measured by an invasive biopsy method and followed by immunohistochemistry (IHC) on the biopsy specimens [8, 30] . It is well known that IHC has serious limitations such as inadequate sampling of the highly heterogeneous primary tumor and lack of information about expression profiles of metastatic lesions. Also, IHC cannot be performed for solid tumors that are inaccessible to biopsy. Alternatively, non-invasive PET imaging could provide a better tool for in vivo imaging of PD-1 checkpoint receptor expression, and it is applicable for dynamic monitoring and overall therapy evaluation. Hence, our goal is to develop a novel tracer to image and quantitatively measure the PD-1 TILs in the tumor microenvironment.
Furthermore, many recent studies have indicated that PD-1 is a sensitive marker in the detection of angioimmunoblastic T cell lymphoma (AITL) and peripheral T cell lymphoma (PTCLU) [51] . These study results demonstrated that PD-1 staining is a highly sensitive marker in the diagnosis of peripheral T cell lymphomas. For example, increased extrafollicular PD-1-positive cells were seen in 93 % (76/82) of AITL, 62 % (16/26) of PTCLU, and 11 % (2/18) of ALK-negative anaplastic large cell lymphomas. Thus, our anti-PD-1 immunoPET tracer could also be readily applicable to image T cell lymphoma patients. In fact, while we were developing this tracer, England et al. [52] developed a similar tracer and tested it on hNSG mice but without a xenografted tumor. In contrast, we used an hNSG mouse model xenografted with a human melanoma tumor, and in addition, we used two different tracers ([ 89 Zr] Keytruda and [
64 Cu] Keytruda) for immunoPET imaging, to measure the amount of TILs homing into the tumor. Further, we administered both tracers with high specific activity, with lower dose regimen per mouse to avoid higher uptake in non-specific organs e.g., liver.
In a previous proof-of-concept study, we developed a radiotracer for mouse PD-1 immunoPET and demonstrated its ability to measure and image TILs in a melanoma xenograft model [53] . These results encouraged us to further develop a human PD-1-targeting PET tracer for clinical translation. In this report, we have shown the development and characterization of an anti-human-PD-1 immunoPET tracer and performed preclinical imaging on a preclinical model of humanized mice bearing melanoma xenografts. Table 1 and Fig. 1 Table 1 ) designed to target human PD-1 using the clinically approved Keytruda mAb. These novel immunoconjugates yielded 1-2 Df or DOTA chelates per antibody and provided greater than 95 % radiochemical purity and high specific activity. The immunoreactivity of the immunoconjugate and immunoPET tracer was 970 % (Fig. 1b and Fig. S2 ) as evaluated by an in vitro live cell binding assay. We are further optimizing the immunoconjugate to enhance the immunoreactivity to reach greater than 80 % for clinical grade preparation.
A FACS study showed that Df-Keytruda has high specificity toward hPD-1, when compared to the naive control that was not induced to express hPD-1 (Fig. S2 ). The radiolabeled Keytruda was then tested on hPD-1 expressing 293T cells, which indicated that the radiolabeling did not significantly affect the binding ability of the antibody toward the target (74 %, Fig. 1b) . Immunoreactivity for [
64 Cu] Keytruda was also performed and it showed 72 % (Suppl. Table 1) .
For preclinical studies, a humanized NSG mouse model was created and characterized for the engraftment of human PBMC by drawing blood from the mouse and tested for the expression of human CD45 and PD-1 by FACS (Fig. 2) . These results indicated successful engraftment of hPBMCs in NSG mice. After administration of the radiotracer in the humanized NSG mouse, the PET image clearly showed the novel immunoPET tracer targeting specifically the human PD-1-expressing TILs that had become home to the tumor and spleen (Figs. 3, 4 , and 5). The hNSG-nblk mouse image at 24 h, corresponding to the [ 89 Zr] Keytruda tracer, demonstrated increased immunoPET signal in both the tumor and spleen (mean %ID/g 4 and 16, respectively; Figs. 3 and 4) as compared to NSG-ctl mice (mean %ID/g 2.9 and 13, respectively), which were not engrafted with human PBMCs. The PET signal from hNSG mice was further analyzed by ex vivo organ imaging (Fig. S5) as well as by a BioD study (Fig. 6a) . 64 Cu] Keytruda. These images clearly indicate that this tracer targets specifically hPD-1-expressing TILs that are homing into the tumor of hNSG-nblk mice (6.4 ± 0.7%ID/g), which exhibit high uptake when compared to the NSG-ctl (2.1 ± 0.5) and NSG-blk (4.4 ± 1.3) mice at 24 h. Tumor-to-muscle ratios (at 24 h) of this tracer show (Fig. S4-b) 7.5 ± 3.6, 29.9 ± 1.7, and 48 ± 8.7 corresponding to NSG-ctl, NSG-blk, and NSG-nblk mice, respectively. Biodistribution at 48 h indicated tumor-to-muscle ratios of 5.4 ± 1.6, 6.2 ± 1.8, and 12.3 ± 2.2 corresponding to NSGctl, NSG-blk, and NSG-nblk mice, respectively. Overall, the PET signal from the tumors corresponding to [
89 Zr] Keytruda and [
64 Cu] Keytruda tracers is high enough to measure in vivo and well delineated from other background tissues, illustrating both their high sensitivity and specificity.
For both tracers, the PET signal in the spleen is due to the spleen's role in priming T cells before deploying them throughout the body for antigen surveillance and attack. The clearance organs, such as liver and kidney, of the three groups of mice (NSG-ctl, hNSG-blk, and hNSG-nblk), at 24 h, show almost similar signal intensity (3-5%ID/g). With respect to muscle, at 24 h, the NSG-ctl, hNSG-blk, and hNSG-nblk mice groups exhibited insignificant PET signal (G0.5%ID/g). In this study, to some extent, we have correlated hPD-1 expression levels to the PET signal. However, further studies will be needed to better understand the dynamics of T cell engraftment in the humanized mouse model. In summary, we performed labeling of Keytruda with two different isotopes ([ 64 Cu] and [ 89 Zr]; half-life = 12.7 h and 78.4 h, respectively), to optimize and select the appropriate tracer for clinical imaging of patients. Tumor-tomuscle ratio data indicated at 24 h that both tracers provide sufficient measurable PET signal to identify tumor delineated from other background tissues.
For immunoPET clinical translation, the following preclinical tracer profiles could be helpful to select favorable isotopes to avoid radioactivity burden on normal tissues. The key parameters are tracer clearance, tumor uptake, and tumor-to-background tissue at the earliest time points between 1 and 24 h. In this study, we have tested two immunoPET tracers ( 
Conclusions
Our study results show that the novel tracers bind in vivo to hPD-1-expressing TILs that have engrafted and homed in the tumor and spleen of our humanized NSG mouse model. Overall, the ease of production and high sensitivity and specificity of our novel Keytruda immunoPET tracers illustrate their feasibility of human translation for imaging in vivo cytotoxic PD-1 T cells. We believe these novel tracers have the potential to screen for patients most likely to respond to immune checkpoint blockade therapy, as well as monitor their responses, and together, these factors will help to greatly enhance patient management and therapeutic outcomes. In summary, our study indicated that both tracers ( 
